Condition (MeSH)
Hypophosphatemia, Familial
ClinicalTrials.gov lists 53 trials for Hypophosphatemia, Familial or a narrower condition beneath it. Kyowa Kirin Co., Ltd. has the most among industry and government lead sponsors, with 10.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
6 of the 53 trials are tagged with Hypophosphatemia, Familial itself; the rest are tagged with a narrower condition beneath it.
When did Hypophosphatemia, Familial trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 5 |
| 2017 | 3 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hypophosphatemia, Familial trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 5 |
| Phase 2 | 3 |
| Phase 3 | 8 |
| Phase 4 | 5 |
| Not applicable | 6 |
| Observational | 20 |
| Expanded access | 1 |
How many Hypophosphatemia, Familial trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 4 |
| Available | 1 |
| Completed | 33 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hypophosphatemia, Familial trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Kyowa Kirin Co., Ltd. | 10 |
| Kyowa Kirin, Inc. | 6 |
| Kyowa Kirin Pharmaceutical Development Ltd | 5 |
| Medialis Ltd. | 1 |
| National Institute of Dental and Craniofacial Research (NIDCR) | 1 |
Which drugs are being tested for Hypophosphatemia, Familial? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Burosumab | 19 |
| Calcitriol | 2 |
| Cinacalcet | 2 |
| Sevelamer | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Burosumab Injection [Crysvita] | 1 |
| Oral Magnesium Supplement | 1 |
| No treatment given | 1 |
| Active vitamin D | 1 |
| norditropine simplex | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hypophosphatemia, Familial trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Arthralgia | 4 | 1 |
| Craniosynostosis | 4 | 1 |
| Migraine | 4 | 2 |
| Myelopathy | 4 | 1 |
| Cervical Spinal Stenosis | 3 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hypophosphatemia, Familial? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Hypophosphatemia in acute liver failure of a broad range of etiologies is associated with phosphaturia without kidney damage or phosphatonin elevation. | Translational research : the journal of laboratory and clinical medicine | 2021 | Yes |
| Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. | The Journal of antimicrobial chemotherapy | 2017 | Yes |
| Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. | AIDS (London, England) | 2016 | Yes |
| Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. | European journal of endocrinology | 2009 | Yes |
| Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. | Circulation. Cardiovascular genetics | 2008 | Yes |
Showing 5 of 20 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.